federal_register: 2022-03926

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2022-03926 Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments Notice The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public meeting entitled "Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA)" (the Program) and an opportunity for public comment. The topics to be discussed are the final assessment and public stakeholder views of the Program. 2022-02-24 2022 2 https://www.federalregister.gov/documents/2022/02/24/2022-03926/final-assessment-of-the-program-for-enhanced-review-transparency-and-communication-in-the-biosimilar https://www.govinfo.gov/content/pkg/FR-2022-02-24/pdf/2022-03926.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public meeting entitled "Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA)" (the...  

Links from other tables